Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
about
Defining the intensity of conditioning regimens: working definitionsThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraDose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphomaReduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrUnrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.Allogeneic hematopoietic cell transplantation: the state of the artClinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureAutologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignanciesA phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsThe allogeneic effect in non-Hodgkin's lymphoma.Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.The role of allogeneic transplantation in non-Hodgkin's lymphoma.Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.The graft-versus-lymphoma effect: clinical review and future opportunities.Stem cell transplantation for mantle cell lymphoma: if, when and how?Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphomaConditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.Cellular therapy following allogeneic stem-cell transplantation.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
P2860
Q24630836-21DE89CA-138D-4235-A861-F2B60925C333Q28072397-5D65BD8C-0078-4B26-A61D-2D317EB64DB9Q33399543-0D1B9914-C118-4117-98A7-DFFFEDC7E4AEQ33419003-20DCD989-4514-4893-83B6-B40136FFD19CQ33743786-BE12FB5E-3BF9-48C1-BC4B-4E9B33DDA850Q33756719-30BC5818-CA80-448A-8C94-FA74E59FCAB2Q33933025-AFF7D64B-BAF0-46CC-9994-66A879A65CCCQ33952823-BE25841C-D2F6-45C9-82A0-FA65B063F5F0Q34044024-95E1FC8A-71B7-4D5D-BF0A-D20EA286EEB9Q34089534-18A56F6F-CF14-4FAE-BAFA-5DE352DC41FEQ34089567-E129CCE5-E1F6-4DFC-884A-A58C5F87FD5EQ34145155-7364828B-4F4B-4C44-874C-AA5BD60059A8Q34365673-E38B6AEE-43AA-48A2-99C4-AF3825C1536BQ34370320-090FE235-03FD-4EF1-83F2-DBE1AA44BF16Q34662648-28C1D3C9-697B-462D-B5AE-4CBDA1E7FCAEQ35038852-A95B9FE2-50CE-403D-8421-43D258F10FF1Q35043077-3C6261F1-8BCB-4A29-B6BE-7EB0C8D674F9Q35061893-5436BCB8-95AE-4964-9399-218313E3C60DQ35115650-FA315666-DA4D-4DD1-8669-C467D7BAF62BQ35139841-C56B06E0-2121-45A6-A6E4-22FEB96E7E80Q35213027-78D05302-B6DC-49F5-A7DF-609DF955506CQ35218515-CA9CB2B7-671D-40EA-AE5C-581239881746Q35223780-7817E20E-B99B-449C-87FF-B8E3C888081FQ35743874-A4E6F657-1E1C-4D8C-AFFA-1308A92D1B74Q35808424-021D9028-7165-4C58-A7F3-93A1F1C44A86Q35852262-6936DD1F-0E28-44B4-8A5B-57055F117021Q35964878-900D1CCF-C042-49FB-A479-AC8D8B1BDC78Q36003103-BA6F4068-7FEE-417A-B5AD-93A52DCF3EA0Q36028751-E2681B81-61CA-4F93-BA74-7398F3089FE2Q36092021-AB371138-49CA-479D-A4C3-04C54B7AAB6DQ36128232-AEE3B0C3-F294-4E98-B58D-201F79CE076DQ36188687-CB452EAF-BEDE-47C0-8DB4-4D6423F43B38Q36219690-6C0CC6B5-B355-41B8-88FD-83113143EB71Q36384668-55D7E04D-BA20-4FE9-8B76-5D65A9E22F13Q36404763-04BF14CD-9358-48C0-AD80-9C77BDA19A13Q36410168-7B52DEC0-E7DD-4B8B-8F24-8F7D3D5BC7E9Q36411719-C6A27631-5650-4759-917E-98C3DBCB07A2Q36612548-1EC301EE-00F3-48A2-9A1B-4C5F86A82B01Q36612643-62C1552A-C14F-4D2C-99C8-1C3BC41A99D7Q36624952-0F7F5CDD-6539-4C05-AC77-48E6A417BBC9
P2860
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@en
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@nl
type
label
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@en
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@nl
prefLabel
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@en
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@nl
P2093
P1433
P1476
Chemoresistant or aggressive l ...... d Bone Marrow Transplantation.
@en
P2093
Angelo Carella
Anthony H Goldstone
Carmen Ruiz de Elvira
Goli Taghipour
Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Nigel Russell
Norbert Schmitz
Stephen Mackinnon
Stephen P Robinson
P304
P356
10.1182/BLOOD-2001-11-0107
P407
P577
2002-08-15T00:00:00Z